Drug intelligence / Profile preview

BN-101A

Development stage: Preclinical
Lead developer: Bio Eleven
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BN-101A is a monoclonal antibody that functions as a PD-L1 inhibitor, blocking programmed cell death ligand 1 (PD-L1) to promote anti-cancer T-cell activity. Developed initially by Scripps Korea Antibody Institute and now advanced by BioEleven Co., Ltd., it has demonstrated efficacy in preclinical models of cancer. Samsung Biologics has partnered with BioEleven for its development and manufacturing as a third-generation cancer immunotherapy.

Other names: anti-PD-L1 antibody (Scripps Korea Antibody Institute)PD-L1 checkpoint inhibitor (Bioeleven)

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on BN-101A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BN-101A.

Explore the full profile